This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Armstrong DK , Alvarez RD , Bakkum-Gamez JN , Barroilhet L , Behbakht K , Berchuck A , Berek JS , Chen LM , Cristea M , DeRosa M , ElNaggar AC , Gershenson DM , Gray HJ , Hakam A , Jain A , Leath CAIii , Liu J , Mahdi H , Matei D , McHale M , McLean K , O'Malley DM , Penson RT , Percac-Lima S , Ratner E , Remmenga SW , Sabbatini P , Werner TL , Zsiros E , Burns JL , Engh AM
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019
J Natl Compr Canc Netw. 2019 Aug 1;17(8) :896-909
PMID: 31390583 URL: https://www.ncbi.nlm.nih.gov/pubmed/31390583
AbstractEpithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years from diagnosis. A major challenge in treating ovarian cancer is that most patients have advanced disease at initial diagnosis. The best outcomes are observed in patients whose primary treatment includes complete resection of all visible disease plus combination platinum-based chemotherapy. Research efforts are focused on primary neoadjuvant treatments that may improve resectability, as well as systemic therapies providing improved long-term survival. These NCCN Guidelines Insights focus on recent updates to neoadjuvant chemotherapy recommendations, including the addition of hyperthermic intraperitoneal chemotherapy, and the role of PARP inhibitors and bevacizumab as maintenance therapy options in select patients who have completed primary chemotherapy. J Natl Compr Canc Netw. 2019 Aug 1;17(8):896-909. doi: 10.6004/jnccn.2019.0039.
NotesExport Date: 1 October 2019